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 2
Abstract  
 
In nonlinear mixed-effects models, estimation methods based on a linearization of the 
likelihood are widely used although they have several methodological drawbacks. Kuhn 
and Lavielle (2005) developed an estimation method which combines the SAEM 
(Stochastic Approximation EM) algorithm, with a MCMC (Markov Chain Monte Carlo) 
procedure for maximum likelihood estimation in nonlinear mixed-effects models without 
linearization. This method is implemented in the Matlab software MONOLIX which is 
available at http://www.math.u-psud.fr/~lavielle/monolix/logiciels. In this paper we apply 
MONOLIX to the analysis of the pharmacokinetics of saquinavir, a protease inhibitor, 
from concentrations measured after single dose administration in 100 HIV patients, 
some with advance disease. We also illustrate how to use MONOLIX to build the 
covariate model using the Bayesian Information Criterion. Saquinavir oral clearance 
(CL/F) was estimated to be 1.26 L/h and to increase with body mass index, the inter-
patient variability for CL/F being 120%. Several methodological developments are 
ongoing to extend SAEM which is a very promising estimation method for population 
pharmacockinetic / pharmacodynamic analyses.   
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Introduction 
Population pharmacokinetics (PK) and pharmacodynamics are increasingly 
performed in drug development and for therapeutic drug monitoring. They are based on 
nonlinear mixed-effects models (NLMEM) and the most popular software in that area is 
NONMEM which was developed by Lewis Sheiner and Stuart Beal (1). In these mixed-
effects models, the problem is that the individual random effects are not observed and 
should be treated as missing data. The usual statistical approach is to integrate them 
out of the joint distribution of the response and the random effects in order to allow 
maximum likelihood estimation. However, for models that are nonlinear with respect to 
the parameters, this integral does not in general have a closed form expression and the 
first ideas was to used first-order approximations. The First-Order (FO) method was 
developed in NONMEM in 1977 (2). The first order conditional estimation method 
(FOCE) was arguably the most significant parametric method to emerge after. Davidian 
and Giltinan (3) explained in detail the technical differences between the various FOCE 
approaches as well as their implementation in various software applications and more 
recent complex approximations. These methods based on an approximated model are 
not true maximum likelihood estimation methods, so that all the nice statistical 
properties of maximum likelihood estimators are not true although they are applied in 
practice, e.g. standard errors derived from the Fisher information matrix, confidence 
intervals based on normality of the estimators, likelihood ratio test for nested models 
and Akaike criterion for model comparisons.  Also, inconsistency of the FOCE 
estimators was demonstrated when the number of subjects increases with a  fixed 
number of observations per subject (4, 5), although it was shown that it was not that 
bad when the residual error variance is "small" compare to the inter-individual 
variability (6). 
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The EM algorithm was first proposed and developed for problems with missing 
data. These are two-step algorithms: the E-step for conditional expectation of the 
needed statistics for the complete data likelihood given the observed data, and the M-
step for maximum likelihood of the complete data (7). They were applied to linear 
mixed-effects models considering the random effects as the missing data (8). However, 
again because of the nonlinear structural model, there was no clear extension of the 
EM algorithm to NLMEM except with approximation during the E-step (9).  
The Bayesian approach fro NLMEM was the first to use computer intensive 
procedures based on Markov Chain Monte Carlo (MCMC) techniques in order to 
propose a solution without approximation. As new and much more rapid software and 
statistical developments became available, interest grew.  
In the maximum likelihood framework, Wei and Tanner (10), Walker (11) and 
Wu (12, 13) propose a Monte Carlo EM (MCEM) where the intractable E-step of EM is 
approximated with an empirical average based on simulated data. Unfortunately, 
MCEM is very time-consuming in computation since it requires a huge amount of 
simulated data. Alternatively, Delyon et al. (14) introduced a stochastic approximation 
version of EM (SAEM), which is more efficient in terms of computation. The stochastic 
approximation method achieves an approximation to the E-step by computing a 
weighted average of the approximation in the current iteration and the ones from all the 
previous iterations. Delyon et al. (14) show that this method converges to the maximum 
likelihood estimate under very general conditions. 
 
Kuhn and Lavielle (15) develop for NLMEM an algorithm which combined the 
SAEM (stochastic approximation version of EM) algorithm (14), with a Markov Chain 
Monte Carlo procedure. They showed the good statistical convergence properties of 
this algorithm. They showed that it is also possible to obtain an approximation of the 
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Fisher information matrix. Then, the inverse of this estimated Fisher information matrix 
provides an estimate of the variance of the maximum likelihood estimator.  
Model selection using AIC and/or BIC and hypothesis testing using the log-
likelihood ratio test (LRT) require the computation of the likelihood of the observations 
under the various models tested. The likelihood however is particularly complex and 
has no close form for nonlinear models. It is accurately estimated by Monte-Carlo 
approaches, using an importance sampling method to reduce the variance of the 
estimation. 
Lavielle developed in 2005 the software MONOLIX which implements this 
algorithm for maximum likelihood estimation in NLMEM without linearization. This 
Matlab software is available at http://www.math.u-psud.fr/~lavielle/monolix/logiciels. 
The objective of this software is to perform: 1) parameter estimation by computing the 
maximum likelihood estimator of the parameters without any approximation of the 
model (linearization, quadrature approximation...) and standard errors for the maximum 
likelihood estimator; 2) model selection by comparing several models using some 
information criteria (AIC, BIC), or testing hypotheses using the Likelihood Ratio Test, or 
testing parameters using the Wald Test; 3) goodness of fit plots; 4) data simulation. 
Because of the absence of linearization in the estimation method, the results are true 
maximum likelihood estimates for which all the statistical properties applied. 
 Saquinavir (SQV) is a protease inhibitor used in treatment of HIV patients. As 
for all protease inhibitors, there is a large PK inter-patient variability. To study more 
specifically the sources of the large inter-patient  PK variability, a specific mono-centric 
trial was performed in patients which received a single dose of saquinavir (16). In order 
to get large variability of the covariates in the studied sample, patients from three 
different groups were included (see Methods).  
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The objectives of the present study were to apply and illustrate MONOLIX on a 
real data set, to estimate the population pharmacokinetic parameter of saquinavir in 
HIV patients in a global population analysis and to test the effects of several covariates 
on saquinavir pharmacokinetics. These data have been previously analyzed with a 
population approach using P-Pharm (9) but with a separate analysis in each group of 
patients, the relationship with covariates being in a second step performed on the 
Empirical Bayes estimates (EBE) of the individual parameters. The same statistical 
model was used with MONOLIX but a preliminary analysis of the data with another 
software is of course not necessary.  
The aim of this paper is not to compare MONOLIX and the SAEM algorithm 
with other existing estimation methods but to show with a real and rather difficult PK 
example that maximum likelihood estimation and model selection is possible with this 
algorithm. Indeed, comparison of estimation methods should be done mainly on 
simulated data where the true answer is known. A blind simulation study comparing 
several software on simulated PK or PD data has been performed by Girard and 
Mentré and presented in 2005 (17); this study showed the very good estimation results 
of SAEM.  
 
 
Methods 
Data 
Concentration data were obtained after single administration of 600 mg of SQV-
HCV alone after a breakfast including 200 ml of grapefruit juice to enhance SQV 
absorption,  in 100 HIV patients who never received protease inhibitor before (16). 
Each patient had three samples collected in 3 periods:  0 to 1.5 h, 2 to 4 h, and 5 to 12 
h. There were a total of 240 concentrations.  Concentrations were assayed by 
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( ; ) ( ; )ij ij i ij i ijy f x g x
radioimmunoassay. The trial design and evaluation biological measurement are more 
detailed in (16). Three groups of patient were enrolled in this prospective trial:  i) 
asymptomatic patients, ii) AIDS symptomatic subjects without diarrhea, iii) AIDS 
symptomatic subjects with diarrhea, but we did not take into account this group effect 
here. Indeed, we focused our study to the estimation of the parameters and the 
selection of the covariate model. 
Eleven covariates were recorded: gender, age, Body Mass Index (BMI), 
creatinine clearance (CLCR) estimated from serum creatinine using the Cokcroft and 
Gault formula, diarrhea (yes/no), mean weight of stools per 24 h, plasma albumine, 
xylose, lactulose/mannitol ratio (L/M), alkaline phosphate level  (APL) and CD4 count. 
Xylose and L/M were obtained as described in (16) to evaluate intestinal absorption 
and permeability, respectively.  
 
Statistical Modelling 
The nonlinear mixed effects model was defined as  
ϕ ϕ ε= + 2~ (0, )ij Nε     ;   σ
i i iA
 
where f is the parametric function of the structural model, g is the parametric function 
for the error model, yij is the jth observation in the ith subject, φI is the p-dimensional  
vector of model parameters for the ith subject, xij are the design variables for the jth 
observation in the ith subject, εij is the residual error for the jth observation, in the ith 
subject and σ2  is the  variance of the residual unidentified variability. In most cases g=f, 
i.e. a proportional error model, or g=1, i.e. an additive error model. 
The random effect and covariate model was defined as  
( )φ μ η= +    ,    
. .
~ 0,  i i i d Nη Ω ,    i=1, …, N, 
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iAwhere  is the covariate (or design) matrix for the i
th subject and assumed to be 
known, μ  is a d-vector of fixed population parameters, iη  is a  p-vector of random 
effects, Ω is the pxp  variance-covariance matrix of the random effect parameters. The 
unknown set of parameters of the model is ( )2, ,θ μ σ= Ω  which is of size P. 
As in [16], a one compartment model with first order absorption after a time-lag was 
used to model saquinavir pharmacokinetics: 
( )( , ; , , , ) exp ( ) exp ( )f D t V Cl ka Tlag t Tlag ka t TlagV ka Cl V + +D ka Cl× ⎡ ⎤= − − − − −⎜ ⎟⎛ ⎞⎢ ⎥× − ⎝ ⎠⎣ ⎦
max(0, )a a+ =
( ),1 ii N j n≤ ≤ ≤
 
where D = 600 mg is the dose and t the time, and where . The design 
variables are  xij = (Di , tij ) (cf remarques ci dessus).Because lognormally distributed 
random effects for each PK parameter (V/F, CL/F, ka and Tlag) was assumed, the 
vector of Gaussian individual parameters φi was composed of  the logarithm of V/F, 
CL/F, ka and Tlag. Two models for the variance of the residual error were tested (g=1 
and g=f). 
 
SAEM algorithm 
We are in a classical framework of incomplete data: the observed data 
is , whereas the random effects, ,1ijy y= ≤ ( ),1i i Nφ φ= ≤ ≤ , are the 
non observed data. Our purpose is to compute the maximum likelihood estimator of θ 
by maximizing the likelihood of the observations ( ),y θl
( )
. 
In the case of a nonlinear function f, the E-step of the standard EM algorithm, 
that consists in computing ( ( ) )( )E log , ; | ;kk ky yQ pθ φ θ θ= , cannot be performed in a 
closed-form. The SAEM (Stochastic Approximation version of EM algorithm), proposed 
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( )k
by Delyon et al. (14) consists in replacing the usual E-step of EM by a stochastic 
procedure (see Kuhn and Lavielle (15) and the user’s guide of MONOLIX for more 
details on SAEM). At iteration k, SAEM consists in three steps:  
• Simulation-step: draw φ  from the conditional distribution ( )1. ; kp y θ − .  
( )• Stochastic approximation-step : update kQ θ  according to  
(( ) ( ) ( ) ( ))( )1 1log , ;kk k k kQ Q p y Qθ θ γ φ θ θ− −= + −
)k
 
   where (γ  is a decreasing sequence of positive numbers.  
( )maxk kArg Qθ• Maximization-step : update kθ  according to    θ θ=   
  For NLMEM, the Simulation-step cannot be performed directly because 
( )1. ; kp y θ −  cannot be found explicitly. To deal with this problem, Kuhn and Lavielle 
(15) propose to combine this algorithm with a MCMC (Markov chain Monte Carlo) 
procedure.  The Hastings-Metropolis algorithm used in MONOLIX combines several 
proposal distributions: the marginal distributions ( )1 1~ ,  i i k kN Aφ μ − −Ω. .i i d and the 
symmetric Gaussian distributions  ( )( 1)
. .
~ ,  ki ii i d Nφ φ − Γ where  Γ is a diagonal matrix such 
that the probability of acceptance is about 0.3. 
It is recommended to set 1kγ =  for 1 k K≤ ≤  and 1kγ = k K−  for k K   (the 
default value in MONOLIX is K=500). Indeed, the initial guess of 
1≥ +
θ  may be far from the 
maximum likelihood value we are looking for and the first K iterations with 1kγ =  allow 
the method to converge quickly to a neighborhood of a maximum of the likelihood. 
Then, smaller step sizes ensure the almost sure convergence of the algorithm to this 
maximum. We combine this stochastic algorithm in MONOLIX with a Simulated 
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( ,1)k
Annealing procedure in order to avoid local maxima and converge to the global 
maximum likelihood estimator. 
 It is possible to slightly improve the results by running L Markov chains instead 
of only one (in MONOLIX, the default value is L=3). The Simulation-step then requires 
to draw L sequences φ , …,  at iteration k and to combine stochastic 
approximation and Monte Carlo in the Stochastic approximation-step: 
( , )k Lφ
( ) ( ) ( ) ( )( , )1 1
1
log , ;k lk k k k
l
Q Q p y Q
L
1 Lθ γ φ θ θ− −
=
⎛ ⎞= + −⎜ ⎟⎝ ⎠∑  θ
The complete log-likelihood can be written 
( ) ( ) ( ) ( )
( ) ( ) ( )
2
1
log , ; log 2 log log
2 2 2
1 1                        
tot tot
N
T ij
n Np N np y
y f
A A
,
2
2
1 ,
log( ( ; ))
;
2 2 ( ; )
ij i
i j
ij i
i i i i
i i j ij i
g x
x
g x
φ θ π
φ μ φ μ−
+= − − Ω − −
−− − Ω − −∑ ∑
σ φ
φ
σ φ=
⎛ ⎞⎜ ⎟⎜ ⎟⎝ ⎠
∑
1
N
tot i
i
n n
=
= ∑
 
where  is the total number of observations. If we consider a diagonal 
covariance matrix  Ω, , the Stochastic Approximation-step consists in updating the 
sufficient statistics of the complete model as follows: 
( )( ) , 1 ; 1,2,...,ki i ks i Nγ φ− −− =
( ) ( )
1 1
N Tk k
kc c cγ φ φ− −⎛ ⎞= + −⎜ ⎟⎝ ⎠∑
( ) 2( )1 1
,
; kk k k ij ij i k
i j
r r y f x rγ φ− −⎛ ⎞⎡ ⎤= + − −⎜ ⎟⎣ ⎦⎝ ⎠∑
, , 1i k i k ks s= +  
   
1
k k k i i
i=
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( )Here, si,k  is a p-vector that approximates 1| ;i kE yφ θ −
T
i i
i
E φ φ⎜ ⎟∑
( ) 2 1
,
; | ;ij ij i k
i j
E y f x yφ θ −⎛ ⎞⎡ ⎤−⎜ ⎟⎣ ⎦⎝ ⎠∑
,  ck  is a p x p-matrix that 
approximates  and r1| ; ky θ −⎛ ⎞⎝ ⎠ ,k is a scalar that approximates 
. 
Then, kθ  is obtained in the Maximization-step as follows: 
1N N
T T ,
1 1
k i i i i k
i i
A A A sμ
−⎛ ⎞= ∑ ∑
= =
⎜ ⎟⎝ ⎠ , 
 ( ) ( ) ( ) ( ), ,
1 1 1
1 N N NT TT
k k i k i k i k i k i k i k
i i i
Diag c A s s A A A
N
μ μ μ μ
= = =
⎧ ⎫⎛ ⎞Ω = − − +⎨ ⎬⎜ ⎟⎝ ⎠⎩ ⎭∑ ∑ ∑ , 
 2 kk
tot
r
n
σ = , 
where Diag(A) is the diagonal matrix formed with the diagonal elements of A.  
It is also possible to obtain an estimation of the Fisher information matrix using 
the Louis’ missing information principle (18, 15). This estimated Fisher information 
matrix converges to the true unknown observed Fisher information matrix when the 
number of iterations increases (see (15) for more details).The inverse of this 
information matrix provides an estimate of the variance of the maximum likelihood 
estimator and the standard errors are obtained without any approximation of the model. 
These standard errors can be used to perform directly a Wald test, for instance for the 
fixed-effects of covariates (19).  
The likelihood is estimated by Importance Sampling also without any 
approximation of the model (15). Then, the likelihood ratio test can be used for testing 
the significance of a covariate in the model. For the test of a variance component to 0, 
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the asymptotic distribution of the likelihood ratio test under the null hypothesis is an 
even mixture of two chi-square distributions with 0 and 1 degree of freedom (20). 
Individual estimates of the parameters are provided by MONOLIX as the mean 
of their posterior distribution. The standard deviations of this posterior distribution, i.e. 
the standard errors of these individual estimates are also provided.  
  
Model Building 
There is no real consensus on the way to do model building in population 
pharmacokinetics (21). We used an approach based on a full population analysis. 
First an univariate analysis was performed using SAEM with the test of each 
covariate on each individual parameter using both a Wald test and a LRT test. Second, 
all population models with all combinations of covariates found significant in the 
univariate analysis were fitted and the best ones were chosen according to the 
Bayesian Information Criteria. This model selection procedure is decomposed in two 
stages: i) for a given dimension of the model, that is for a given number of covariates, 
select the model with the greatest likelihood (or several models if their likelihoods are 
very close), ii) compare these best models using an information criteria (we used BIC) 
for selecting the dimension of the final model.  
Third we tested using both a Wald test and a LRT whether each covariate that 
remained in the final model was significant and we looked at the change in interpatient 
and residual variability when this covariate was included or not.  
 
 
Results 
Observed concentrations of saquinavir are displayed Figure 1. Without any 
covariate in the model, the best error model was an homoscedastic additive error 
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model as in Trout et al. (16). The Wald test and the LRT test also led us to keep 
random effects on all the parameters. SAEM as implemented in MONOLIX was able to 
estimate the four fixed effects and the variance of the four random effects with good 
precision. As in Trout et al. (16), the inter-patient variability was found to be very large 
especially for CL/F and V/F with coefficient of variations (CV), approximated as the 
standard deviation of η, of 127% and 176%, respectively. We then fit the eleven 
models with only one covariate in the model: in the univariate analysis, the Wald test 
and the LRT always agreed and six covariates were found to be significantly 
associated with CL/F (Table 1): BMI (p=0.0024), diarrhea (p=0.0027), CD4 count 
(p=0.014), creatinine clearance (p=0.021), lactose/mannitol ratio (p=0.033) and xylose 
(p=0.037). All these covariates are highly correlated and in Trout et al. (16), in the 
analysis of log(AUC), only BMI and log(xylose) were found to remain significant.  
We then estimated with SAEM all the models with several of these six 
covariates (Table I). The lowest BIC was found for model 4 with only the covariate BMI 
which was positively associated with CL/F and with a change in BIC compared to the 
basic model with no covariate of 3.82 which can be considered as an important 
improvement (22). The second best model, model 6, had the effect of diarrhea 
decreasing CL/F and had a slightly higher BIC (change of 3.47). All models with two or 
more covariates had higher BIC and some of these models with BMI and/or diarrhea as 
a covariate are displayed in Table I. The best model with two covariates was with both 
BMI and diarrhea (model 14) but with a change of BIC from the basic model of only 1.1 
and the Wald test for diarrhea was no longer significant. When BMI (diarrhea 
respectively) was incorporated in the model the inter-patient variability on CL/F 
dropped only to 119% (118% respectively) and inter-patient variability on V/F dropped 
to 156% (157% respectively). Because the model with BMI and the model with diarrhea 
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had very closed BIC we chose that to present the results of those two models. The 
choice of a final model between model 4 and model 6 depends on the purpose of the 
model building. The distribution of BMI conditionally to diarrhea is displayed Figure 2. 
We see that these two covariates are strongly negatively correlated: the BMI mean 
(SD) is 22.47 (0.42) in the group without diarrhea and 18.16 (0.80) in the group with 
diarrhea (p-value = 6 10-6).  
The estimated parameters of these two models are given in Table II, and the 
standard errors of estimation were good even for all the inter-patient variances. The 
standard deviations of the residual error were 9.24 ng/ml (model 4) and 9.26 ng/ml  
(model 6) which is rather small compared to the range of observed concentrations.  
The increase (respectively decrease) of individual estimated values of log(CL/F) 
and of the corresponding random effect with BMI (respectively diarrhea) in the fitted 
model without covariate is displayed Figure 3. The model for CL/F without covariate is 
log(CL/F)=μCL/F+bCL/F with μCL/F=0.23, then the left-hand and right-hand sides of this 
figure are identical, up to a shift on the y-axis of μCL/F=0.23. These relationships 
obtained with model 4 (BMI as a single covariate) are displayed Figure 4. The 
relationship between log(CL/F) and BMI is well described with the linear model as no 
relationship remained between the individual random effects and BMI.  Also, the means 
of log(CL/F) in the groups with and without diarrhea are significantly different but not 
the means of the individual random effects, which show that the model with BMI 
captures the diarrhea effect. Similar results obtained with model 6 (diarrhea as a single 
covariate) are displayed Figure 5, but it can be seen that with this model the BMI effect 
is not totally explained by diarrhea as some  relationship between individual random 
effects and BMI remained. 
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Several goodness of fit plots are displayed in Figure 6 and illustrate the quality 
of model 4 with BMI. Very similar goodness of fit plots are obtained with diarrhea 
instead of BMI. 
An example of the convergence of the SAEM algorithm for model 4 with BMI 
from rather poor estimate is displayed on Figure 7. In this example, the total number of 
iterations is 2000 decomposed into K=1000 iterations with γk = 1 and 1000 iterations 
with γk = 1/(k-1000). We used L = 5 independent Markov chains. Using these 
parameters, the computing time of the SAEM algorithm is about 1 minute on a labtop 
with a 1.6 GHz processor. A logarithmic scale is used for the x-axis to show that SAEM 
converges in very few iterations to a neighborhood of the maximum likelihood estimate 
when the stepsize γk = 1. The default values proposed in Monolix (L=3, K=300) are 
convenient for estimating roughly the parameters of the model, but not large enough in 
this example to compute accurate estimations of the standard errors and of the 
likelihood of the model.  
 
 
Discussion  
The results found on the population PK of saquinavir in this sample of patients 
are in accordance to those of the previous analysis (16), although we used here a 
different approach. Indeed we analyzed all the patients together and covariate model 
building was not based on individual estimates but on full population models at each 
step. We found that CL/F increased with BMI, or decreased with the presence of 
diarrhea which can be explained by a higher bioavailability of saquinavir in patients with 
severe body loss or diarrhea, although no effect was found of V/F. The physiological 
reasons have been discussed deeply by Trout et al. (16). The enhancement in 
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g( ) log( )totL P n
saquinavir bioavailability could be due to the destruction of the transporters in 
enterocytes and/or to the enlargement of their tight junctions, allowing a paracellular 
crossing of saquinavir as the illness spreads. It should be noted that in this analysis, by 
construction of the three groups of inclusion, a third of the patient had severe body loss 
and/or diarrhea. The inter-patient variability of saquinavir was very high for V/F and 
CL/F even in the final models with BMI and/or diarrhea taken into account. 
 We defined the best error model based on the Bayesian Information Criteria 
which is usually defined in the literature (23) as 2lo− +
2 log( ) 2
, where L is the 
likelihood, ntot the total number of observations and P the total number of parameters to 
be estimated in the model. This choice is quite arbitrary and several other information 
criteria could be used. First, there is a discussion of which size should enter in the 
penalty function since BIC is a consistent criteria when the number of patients N 
increases. Thus, for testing the inclusion of covariates, the total number of patients N 
might be more appropriate than the total number of observations ntot in the penalization 
term of BIC. The Akaike Information Criteria (AIC) defined as L P− + is also 
very popular, but it is not consistent and usually overfits the model. AICc is a second 
order bias correction version of AIC defined as AICc = AIC + 2P(P+1)/(N-P+1) and that 
should be used instead of AIC when N is small (see 24 for more details). In AICc we 
use N for the correction but, as for BIC, it is not clear whether N or ntot should be chose. 
These four different information criteria are displayed Figure 8 as a function of the 
number of covariates in the model with, for each number of covariate, the best model. 
We see that the model with the lowest BIC was the same with the two penalties (ntot or 
N) and includes only one covariate while the model with the lowest AIC and the lowest 
AICc includes three covariates (model 23). This model has an effect of CD4, BMI and 
diarrhea, but with the Wald test none of these three covariates are significant, 
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illustrating the overfit described for model bulding based on AIC. A more complete 
analysis of these criteria is beyond the scope of this paper. 
There is no real consensus on the strategy to perform model building in 
population PK/PD analysis and the number of models to evaluate could be quite large. 
For instance here there are four PK parameters and eleven covariates that were 
tested. We did a first screening of the covariate using the Wald test which had here 
similar results as the LRT. Further developments on covariate model building in 
nonlinear mixed effects models should be done and of course model selection depends 
of the purpose of the model. 
 One main feature of the SAEM algorithm is that it does not need an 
approximation of the likelihood. It is a stochastic extension of the EM algorithm. 
MONOLIX, which implements SAEM also provide an estimation of the likelihood and of 
the Fisher information matrix without linearization of the model so that both LRT and 
Wald test are more reliable then with estimation methods based on approximation of 
the likelihood.  Similarly, the full posterior distribution of the random effects is computed 
and the EBE are defined as the mean of this distribution. MONOLIX also provides 
standard error on the EBE. Automatic and optimal choice of the parameters of the 
SAEM algorithm  (number of iterations, sequence γk, number of chains…) is a rather 
difficult problem. The default values proposed in MONOLIX 1.1 (L = 3, K = 300) were 
convenient for estimating roughly the parameters of the model but were not large 
enough to compute accurate estimations of the standard errors and of the likelihood of 
the model. It should be noted that this analysis presents a challenging problem in term 
of estimation, because the number of observations per individual (at most three) is 
smaller than the number of parameters in the PK model (four) and there is also a very 
large inter-patient variability. 
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Several extension of MONOLIX are under developments. First for models 
defined as ordinary differential equation we proposed to use a numerical procedure 
based on local linearization (25) to speed up the algorithm compared to standard 
Runge-Kutta numerical approximation methods (26). We are working on a version of 
MONOLIX that could handle left-censored data, as for instance concentration below 
the limit of quantification. Indeed these data can be considered as missing data and 
SAEM can be extended using the fact that they are additional missing data to the 
random effects. We are also working on the incorporation of a third level of variability to 
model for instance variability between occasions.  
We also proposed to use MONOLIX in population design evaluation, for 
estimation of the expected information matrix without linearization (27) as an extension 
of PFIM based on a first-order linearization (28). A very large data set under the 
proposed design is simulated and then fitted with SAEM. The estimated information 
matrix from that fit is close to the expected information matrix and can easily be scaled 
to the number of patients that was initially scheduled.  
In conclusion, as results of population PK/PD analyses are increasingly used for  
designing new trials, for instance trough clinical trial simulation, new methods without 
approximation of the likelihood that provides more reliable estimates and standard 
errors are needed. In the maximum likelihood framework extension to the EM 
algorithms have been proposed to that end (29). MONOLIX implements SAEM in 
Matlab and is a free software available at http://www.math.u-psud.fr/~lavielle. It is 
based on a thorough statistical theory (14, 15) and several statistical developments are 
ongoing. MONOLIX is a fast and efficient algorithm as illustrated in this real example 
with a sparse design and large inter-patient variability.   
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Table I: For the basic model and several models with one, two or three covariates 
on log(CL/F): Log-likelihood (LL), BIC and estimated fixed effects (β) of the 
covariates with the corresponding p-value of the Wald test  
Model Cov 1 Cov 2 Cov 3 LL BIC β1 pval1 β2 pval2 β3 pval3
1    -1241.48 2482.96       
2 Sex   -1240.85 
       
2487.18 0.416 0.2651     
3 Age   -1240.82 
       
2487.12 -0.013 0.4475     
4* BMI   -1236.83 
       
2479.14 0.107 0.0024     
5 CLCR   -1239.61 
       
2484.70 0.013 0.0211     
6* Diarrhea   -1237.00 
       
2479.48 -0.982 0.0027     
7 CD4   -1238.40 
       
2482.28 0.002 0.0144     
8 Xylose   -1239.95 
       
2485.38 0.599 0.0367     
9 L/M   -1240.05 
       
2485.58 -4.677 0.0326     
10 St. weight   -1240.61 
       
2486.70 -0.001 0.2333     
11 APL   -1239.98 
       
2485.44 -0.001 0.1606     
12 Albumine   -1240.13 
       
2485.74 0.029 0.1590     
13 CLCR BMI  -1236.13 
       
2483.22 0.007 0.2124 0.093 0.0097   
14 Diarrhea BMI  -1235.14 
       
2481.24 -0.677 0.0590 0.078 0.0368   
15 CD4 BMI  -1236.28 
       
2483.52 0.001 0.0875 0.093 0.0090   
16 Xylose BMI  -1236.28 
       
2483.52 0.360 0.2178 0.095 0.0131   
17 L/M BMI  -1236.30 
       
2483.56 -2.263 0.2940 0.099 0.0076   
18 CLCR Diarrhea  -1235.39 
       
2481.74 0.010 0.0873 0.897 0.0076   
19 CD4 Diarrhea  -1235.53 
       
2482.02 0.001 0.0986 -0.820 0.0155   
20 Xylose Diarrhea  -1236.74 
       
2484.44 0.274 0.3482 -0.845 0.0180   
21 L/M Diarrhea  -1237.16 
       
2485.28 -2.524 0.2961 -0.830 0.0295   
22 CLCR BMI Diarrhea -1234.28 
       
2485.00 0.006 0.2692 0.062 0.1129 -0.625 0.0773 
23 CD4 BMI Diarrhea -1233.82 
       
2484.08 0.001 0.1694 0.069 0.0603 -0.537 0.1321 
24 CLCR CD4 Diarrhea -1234.80 
       
2486.04 0.009 0.1220 -0.001 0.1280 -0.716 0.0382 
25 CLCR BMI CD4 -1235.42 
       
2487.28 0.007 0.2440 0.077 0.0394 0.001 0.0845 
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* The two models with the smallest BICTable II: Estimated population 
pharmacokinetic parameters of saquinavir with the two final models 
 Model 4 Model 6 
 Estimate SE (CV %) Estimate SE (CV %) 
 exp(μCL/F) in L/h 1.26 0.19 (15%) 1.25 0.18 (15%) 
βBMI_CL/F* 0.11 0.04 (33%) 
(p-value = 0.0024) 
  
βDIARRHEA_CL/F*   -0.98 0.33 (33%) 
(p-value = 0.0027) 
exp(μV/F) in L 0.86 0.22  (26%) 0,96 0.24 (25%) 
exp(μka) in h-1 0.58 0.05 (9%) 0.61 0,05 (8%) 
exp(μTlag) in h 1.13 0.12 (11%) 1.12 0.12 (12%) 
ωCL/F2 1.41 0.30 (22%) 1.38 0.29 (21%) 
ωV/F2 2.43 0.65 (27%) 2.45 0.60 (24%) 
ωka2 0.22 0.07 (29%) 0.17 0.05 (28%) 
ωTlag2 0.51 0.13 (25%) 0.53 0.12 (23%) 
σ2   in (ng/ml)2 85.3 12.5 (15%) 85.7 12.8 (15%) 
 
*Effect on log(CL/F)
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Figure 1:  Observed individual concentrations (in ng/ml) of saquinavir  
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Figure 2: Distribution of BMI conditionally to diarrhea 
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Figure 3:  For model 1 fitted without any covariate, relationships between 
individual log(CL/F) and BMI (top left), individual random effects for log(CL/F) 
and BMI (top right), individual log(CL/F) and diarrhea (bottom left),  individual 
random effects for log(CL/F) and diarrhea (bottom right). 
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Figure 4:  For model 4 fitted with the covariate BMI on log(CL/F), relationships 
between individual log(CL/F) and BMI (top left), individual random effects for 
log(CL/F) and BMI (top right), individual log(CL/F) and diarrhea (bottom left),  
individual random effects for log(CL/F) and diarrhea (bottom right). 
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Figure 5:  For model 6 fitted with the covariate diarrhea on log(CL/F), 
relationships between individual log(CL/F) and BMI (top left), individual random 
effects for log(CL/F) and BMI (top right), individual log(CL/F) and diarrhea 
(bottom left),  individual random effects for log(CL/F) and diarrhea (bottom right). 
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Figure 6:  Goodness of fit plots for model 4 (BMI on CL/F). Top: observations 
versus predictions (in ng/ml), with on left population prediction and on right 
individual predictions; bottom: residuals versus time, with on left population 
residuals and on right individual residuals 
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Figure 7: Example of convergence of SAEM with model 4 from poor initial 
estimates 
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Figure 8:  Four different Information criteria for selecting between 0 and 6 
covariates: BIC using the total number of observations in the penalization term 
(BICN), BIC using the number of individuals in the penalization term (BICntot), AIC 
and corrected AIC (AICc).  
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